Small Businesses are Better Equipped to Prevent Cybercrime. DHS’s Recent Funding Will Aid Their Research.

 

Since the inception of the internet, cybercrime has been a concern. The escalating wave of cyber threats necessitates cutting-edge defenses to safeguard our digital realm. Recognizing this, the Department of Homeland Security (DHS) has recently awarded $3.15 million to 20 small businesses for proof-of-concept research in cybersecurity. Given that small businesses contributed to 44 percent of U.S. economic activity in 2020, this support can drive vital innovations in the field.

But, does this funding program go far enough, and what additional areas of research should be prioritized? Does this mark a paradigm shift in how we approach the fight against cybercrime?

Examining this recent funding, Joan Ross, an Adjunct Cybersecurity Professor at St. Martin’s University, posed several questions on this. She offered insight into the seven areas of focus within the DHS program and presented her views on further areas that require exploration and funding.

Ross further explored:

  • The essentiality of accurate real-time detection in the current cyber threat landscape.
  • The importance of focusing on supply chain capabilities, first responder credentialing, and reduced order modeling of critical infrastructure.
  • Ross’s call for additional funding for behavioral analysis combined with data science and exploration of passive observation capabilities.

Joan Ross brings over 30 years of experience as a technologist and working professional in the cybersecurity industry. As an adjunct professor of Incident Response at St. Martin’s University, her insights stem from deep experience and a firm grasp of the ongoing changes in the cybersecurity landscape.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More